Epstein-Barr virus vaccine development: A lytic and latent protein cocktail

Timothy D. Lockey, Xiaoyan Zhan, Sherri Surman, Clare E. Sample, Julia L. Hurwitz

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Epstein-Barr Virus (EBV) is the causative agent of acute infectious mononucleosis and associates with malignancies such as Burkitt lymphoma, nasopharyngeal carcinoma, and non-Hodgkin's lymphoma. Additionally, EBV is responsible for B-lymphoproliferative disease in the context of HIV-infection, genetic immunodeficiencies and organ/stem-cell transplantation. Here we discuss past and current efforts to design an EBV vaccine. We further describe preliminary studies of a novel cocktail vaccine expressing both lytic and latent EBV proteins. Specifically, a tetrameric vaccinia virus (VV) -based vaccine was formulated to express the EBV lytic proteins gp350 and gp110, and the latent proteins EBNA-2 and EBNA-3C. In a proof-of-concept study, mice were vaccinated with the individual or mixed VV. Each of the passenger genes was expressed in vivo at levels sufficient to elicit binding antibody responses. Neutralizing gp350-specific antibodies were also elicited, as were EBV-specific T-cell responses, following inoculation of mice with the single or mixed VV. Results encourage further development of the cocktail vaccine strategy as a potentially powerful weapon against EBV infection and disease in humans.

Original languageEnglish (US)
Pages (from-to)5916-5927
Number of pages12
JournalFrontiers in Bioscience
Issue number15
StatePublished - May 1 2008

All Science Journal Classification (ASJC) codes

  • General Biochemistry, Genetics and Molecular Biology
  • General Immunology and Microbiology


Dive into the research topics of 'Epstein-Barr virus vaccine development: A lytic and latent protein cocktail'. Together they form a unique fingerprint.

Cite this